Exchange: NASDAQ·Updated 04:10 PM EST

COCH News

News
all
press releases
Envoy Medical, Inc. (COCH) Reports Q3 Loss, Tops Revenue Estimates
Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of +28.57% and +10.00%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Envoy Medical, Inc. (COCH) Reports Q3 Loss, Tops Revenue Estimates
Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of +28.57% and +10.00%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Sight Sciences (SGHT) delivered earnings and revenue surprises of 0.00% and +6.46%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
IQVIA (IQV) delivered earnings and revenue surprises of +3.09% and +1.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Zacks
Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of +22.22% and -15.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Envoy Medical completed three-month visits for all 56 patients in its Acclaim cochlear implant trial as it moves toward an FDA PMA submission.read more...
Benzinga
Here is how Humana (HUM) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Zacks
AngioDynamics (ANGO) delivered earnings and revenue surprises of +36.36% and +7.61%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.